FDA approves Sanofi's Toujeo

Sanofi (Euronext:SAN; NYSE:SNY) said FDA approved its Toujeo insulin glargine to improve glycemic control in adults with Type I and Type II diabetes. Sanofi expects to launch the drug and announce its price early next quarter.

The 300 units/mL formulation of insulin glargine, a synthetic sustained-release subcutaneous insulin analog, is intended to provide prolonged duration of action compared to the pharma's Lantus insulin glargine (100 units/mL) at single subcutaneous doses. Sanofi has said that it expects Toujeo to eventually replace Lantus, which had 2014 sales of EUR 6.3 billion ($7.2 billion). ...